Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MaxCyte, Inc. is a biotechnology company that develops and commercializes cell-engineering technologies used primarily in cell and gene therapy, drug discovery, and bioprocessing. The company’s core offering is a proprietary electroporation-based platform that enables the efficient, scalable, and reproducible modification of a wide range of cell types, including immune cells and stem cells. MaxCyte generates revenue through instrument sales, consumables, licensing, and strategic partnerships with biotechnology and pharmaceutical companies.
The company serves biotechnology firms, large pharmaceutical companies, and academic or research institutions developing next-generation therapeutics such as CAR-T, CAR-NK, TCR therapies, gene-edited cell therapies, and viral vector–based products. MaxCyte is positioned as a platform technology provider rather than a therapeutic developer, which allows it to participate broadly across multiple programs and indications without assuming clinical development risk. Founded in 1998, the company evolved from an early focus on electroporation research into a commercial platform business and became a publicly traded company in 2021.
Business Operations
MaxCyte operates through a single integrated business model centered on its Cell Engineering Platform, which includes its ExPERT instruments, proprietary consumables, and associated software. Revenue is primarily generated from the sale of instruments and single-use processing assemblies, as well as licensing and milestone-based payments from strategic platform partnerships. The company also earns potential future royalties tied to the commercial success of partner-developed therapeutics that use MaxCyte technology.
Operations are global, with customers across North America, Europe, and Asia-Pacific. MaxCyte controls its core electroporation technology, manufacturing processes for consumables, and intellectual property portfolio, which includes a significant number of issued and pending patents. The company maintains long-term strategic partnerships with multiple biotechnology and pharmaceutical companies, including platform licenses that cover preclinical, clinical, and commercial-scale cell therapy manufacturing.
Strategic Position & Investments
MaxCyte’s strategic direction focuses on expanding adoption of its platform in clinical-stage and commercial cell and gene therapy programs. Growth initiatives include increasing the number of licensed clinical programs, supporting partners as they advance toward late-stage trials and commercialization, and expanding applications of its technology into new cell types and therapeutic modalities. The company emphasizes recurring, high-margin revenue from consumables and downstream royalties as programs progress.
Rather than acquiring therapeutic assets, MaxCyte invests in long-term platform partnerships that embed its technology into customers’ development pipelines. Notable partnerships include broad platform agreements with large biopharmaceutical companies, providing potential milestone payments and future royalties. The company is also involved in emerging areas such as gene editing using CRISPR-based systems and next-generation immune cell therapies, where scalable and consistent cell engineering is critical.
Geographic Footprint
MaxCyte is headquartered in North America, with its principal executive offices in the United States. The company maintains a significant operational presence in Europe, including manufacturing and research activities, and serves customers across Asia-Pacific through direct sales and distribution channels. Its platform is used by customers in more than 20 countries, reflecting a broad international footprint.
While the majority of revenue is generated from customers in the United States and Europe, MaxCyte’s strategic partnerships often involve multinational clinical programs with global development and commercialization plans. This gives the company indirect exposure to worldwide regulatory pathways and commercial markets without maintaining extensive physical infrastructure in every region.
Leadership & Governance
MaxCyte is led by an executive team with experience in biotechnology, life sciences tools, and cell therapy manufacturing. The leadership emphasizes a platform-based growth strategy, disciplined capital allocation, and long-term value creation through partnerships rather than direct therapeutic development.
Key executives include:
- Doug Doerfler – President and Chief Executive Officer
- Jeffrey Miller – Chief Financial Officer
- Erik Mikkelsen – Chief Technology Officer
- Doug Adams – Senior Vice President, Global Commercial Operations
- Charlie McDonagh – Senior Vice President, Legal and Corporate Affairs
The company operates under a board-governed structure consistent with U.S. public company standards, with oversight of strategy, risk management, and executive compensation in alignment with shareholder interests.